$75M Milestone Payment from J&J
Et Tu, Ibrutinib? Pharmacyclics NDA in Lymphomas Accepted
By Randy Osborne
Staff Writer
Staff Writer
Thursday, August 29, 2013
Pharmacyclics Inc. gained a $75 million milestone payment from Johnson & Johnson (J&J) unit Janssen Biotech Inc. for progress with the oral Bruton’s tyrosine kinase inhibitor ibrutinib, and the future looks even brighter for the compound, if the FDA grants approval.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.